← Eichor
Study identifier: NCT07476287 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

Condition: Small Cell Lung Cancer · Small Cell Lung Cancer ( SCLC ) · Transformed Small Cell Lung Cancer  ·  Sponsor: Pfizer

PhasePhase 2
Planned participants40
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The study is for adults with Transformed Small Cell Lung Cancer (T-SCLC ). T SCLC is a rare lung cancer that happens when one type of lung cancer changes into a more aggressive type after treatment stops working. To join the study, participants must meet the following conditions: * Are aged 18 years or older * Diagnosed with T-SCLC and have not received treatment for this type of lung cancer (a single cycle of chemotherapy may be permitted) * Prior diagnosis of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors (TKIs) * Have healthy organs based on medical tests and are in good physical condition After joining the study, adults will be given chemotherapy in addition to the study medicine. After this combination treatment is finished, the study medicine will be continued alone. Adults will receive the treatment through IV infusions (medicine given directly into a vein). All treatments will be done at clinical study sites, where a trained medical team will monitor adults during and after each visit.

This description comes directly from the study's public registry record.

Talk to the study team

Pfizer CT.gov Call Center  ·  1-800-718-1021  ·  ClinicalTrials.gov_Inquiries@pfizer.com

Always discuss trial participation with your own doctor first.

Locations (12)

City of Hope National Medical CenterDuarte, California, United StatesRecruiting
City of Hope Lennar Foundation Cancer CenterIrvine, California, United StatesRecruiting
Hope and Healing Clinical ResearchHinsdale, Illinois, United StatesRecruiting
Hope and Healing Clinical ResearchNew Lenox, Illinois, United StatesRecruiting
Peking Union Medical College HospitalBeijing, Beijing Municipality, ChinaNot Yet Recruiting
Union Hospital Tongji Medical College Huazhong University of Science and TechnologyWuhan, Hubei, ChinaNot Yet Recruiting
Shanghai Chest HospitalShanghai, Shanghai Municipality, ChinaNot Yet Recruiting
Sheba Medical CenterRamat Gan, HA Merkaz, IsraelRecruiting
Shaare Zedek Medical CenterJerusalem, Jerusalem, IsraelRecruiting
Japanese Foundation for Cancer ResearchKotoku, Tokyo, JapanRecruiting
National Cheng Kung University HospitalTainan, TaiwanNot Yet Recruiting
National Taiwan University HospitalTaipei, TaiwanNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07476287